| 摘要 |
The present invention relates to a composition for prevention or treatment of obesity, dyslipidemia, fatty liver or insulin resistance syndrome comprising camphene as active ingredients. The composition comprising camphene as active ingredients according to the present invention suppresses adipocyte differentiation and reduces the body fat mass, amount of visceral fat, total cholesterol concentration and triglycerides in plasma and liver tissues, which ultimately leads to the prevention or treatment activity in obesity, hyperlipidemia or fatty liver. In addition, the composition of the present invention induces a significant reduction in fasting blood sugar and serum insulin levels to thus improve Type 2 diabetes or insulin resistance as well as metabolic diseases associated therewith. Moreover, the composition of the present invention significantly reduces the expression of nuclear transcription factors (C/EBPa and PPAR?2) and a target gene (ap2) thereof, which play pivotal roles in generation of adipose tissues in visceral adipose tissues, thereby exerting suppression effects on the amount of visceral fat, and the expression of cytokine (TNF-a or IL-6) that activates inflammation, thereby improving chronic inflammatory activation induced by obesity in visceral adipose tissues. Further, the composition of the present invention increases the expression of UCP (UCP1 or UCP3) genes that regulate heat generation in vivo, thereby improving the phenomenon of inhibition on heat generation induced by obesity in visceral adipose tissues. |
